News

FedEx Corp. (FDX) reported mixed results for its third quarter, falling short of analyst expectations on earnings but exceeding them on revenue. The company reported earnings of $4.51 per share, missing the consensus estimate of $4.54, while revenue came in at $22.2 billion, surpassing the $21.89 billion estimate.

Micron Technology Inc. (MU) surpassed analyst expectations in its second quarter, reporting revenue of $8.05 billion and adjusted earnings per share of $1.56. The company anticipates record quarterly revenue in fiscal Q3 and is on track for record revenue and significantly improved profitability in fiscal 2025.

Peter Schiff, a prominent Bitcoin critic, warns that the strategic Bitcoin reserve is a tool to trick Americans into speculative losses. He specifically criticizes President Donald Trump's involvement in promoting cryptocurrencies, predicting that more Americans will lose money in crypto under his influence than in any other speculative mania in history.

B. Riley Securities initiated coverage on ArriVent Biopharma, a clinical-stage biopharmaceutical company focused on developing cancer treatments. The firm believes ArriVent's lead drug candidate, firmonertinib, has the potential to be a superior treatment option for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations and PACC mutations, representing a significant market opportunity.

Monte Rosa Therapeutics' Phase 1 study of MRT-6160 demonstrated promising results, with sustained VAV1 degradation and suppression of T and B cell activation, paving the way for Phase 2 studies and potential applications in immune-mediated diseases. The company's collaboration with Novartis and strong financial position further bolster its prospects.